In-Silico Drugmaker Highlights Rapid Rx Development at BIO Investor Forum

 BIO Investor Forum meeting October 21, 2015, Parc 55 Hilton Hotel, San Francisco. Cyclica is an emerging biotech firm that invented a therapeutic platform based on technologies. It’s called the Ligand Express (TM). The company is now in a license deal with Johnson & Johnson . They repurposed a pharmaceutical product made in the US. The DoD asked them to weed out 2000 drugs down to 53 and eventually they selected one, Zoloft. It turns out that this drug works against Ebola. The Army’s recent deployment of 3000 people to Africa to set up field hospitals, used Zoloft to treat Ebola patients.

Another example, Procter & Gamble has a drug compound that was causing skin irritation in some people that use their Olay skin cream products. It caused a rash. The company isolated three compounds that cause the issue and then eliminated the compound. 

The company’s vision is to 

  •  Cut drug development costs in half
  •  FDA to approve their drugs and 
  • Be the best tech platform for every doc to do personalized medicine solution in the future. 

The goal is to create an automated platform compared to other in-Silico players. Other in Silico firms look for chemogenic compounds, but this company does it all via Ligands. The company’s business model is mainly to work with big pharmaceutical and nutraceutical projects. 

The platform is like the eBay platform. For example on a project basis they might get $10,000 $20,000 in revenue with this model. The second thing they would do is have a license model in which they would receive $25,000 or more per project. 

Their current prospects include Procter & Gamble, the Department of Defense or other similar types of firms. The CEO’s name is Paul Angelico. He said that they will need $20 million in cash by 2019. They currently seek $9.5 million from VC investors.

Big Data and Precision Medicine Trending at CHI Tri-Con in SF

Moscone North Hall, Feb. 17, 2015. After walking the halls in the exhibit area at the recent annual CHI Tri-Con event in San Francisco, I discovered that a theme came together after I passed by various booths.

For one thing, the words “precision medicine” seemed to be resonating among those firms that were exhibiting and I asked some of them, “Is that the same thing as “personalized medicine” or “individualized medicine?”” I noted to that person that President Obama had recently made some kind of a speech that was promoting the idea of precision medicine so maybe the time has come for precision medicine to take the spotlight.

In any event I also found that there are other themes there such as big data. It is being used in a number of different biomedical research areas. I stopped by the Illumina booth spoke with the lady there whose name was Kathleen. She said that she had just joined the company about two months ago from Roche where she was involved in the clinical area. She said that her firm is moving into the data management side of their business with a focus on clinical diagnostics and take advantage of the fact that a lot of NexGen sequencing is now being used for clinical types of applications and will be generating lots and lots of data.  So big date is the theme here as well. They’re hoping to sell their systems into the clinic and hospital type settings so that they develop some very useful software systems to make sense of all that data. Data analytics is going to be a big deal.

I walked around and came across another booth that was also telling the story of powerful computer power and big data and that was the guy at Cray Computer that is famous for supercomputers in the past, but today they are using many many computers together as a cluster, a Hadoop and have another one they called SPARK. I’ll have to check out what “Spark” means. It seems to me that quite a lot is happening in the software.

CHI had other usual events that they have at the Exhibit Hall such as a raffle in which an attendee might win some kind of electronic gadget. This part of the event also featured a discussion tables. There were 40 tables that could handle as many as 8 to 10 people.  I noticed that just about every table was filled up in the hall and some of the tables had probably 10 to 15 people there, so they must have had some very popular topics to discuss. Traditionally, this part of the exhibit area has been very popular in past meetings that I’ve attended.

Simple Cancer Biomarkers are Inadequate to Enable Personalized Medicine

It seems that researchers are finding that using single cancer biomarkers to develop companion diagnostics (CDx’s) to be used with future targeted therapeutics is very challenging. An article in the November 15 issue of Genetic Engineering and Biotechnology News, called Traversing the Cancer Biomarker Labyrinth, by Kathy Liszewski, is a very interesting read.

Apparently progress in this field has slowed in finding clinically useful biomarkers for diagnostics and making other tests that guide doctors for disease prognosis and prediction. Researchers are using a variety of reductionist technical approaches that range from analysis of certain glycans, key microRNAs, and epigenetic changes, to big data analysis of massive data stores of genomic data to tease out more clues to what is going on in cancers.

Scientists seek to develop early detection blood tests that can detect cancers of interest.  Such a blood test could be considered a ‘liquid biopsy’ and might include a panel of a dozen or more miRNAs that represent a biomarker signature.  An oncologist might one day be enabled to quickly screen certain patients with a blood test that would help them diagnose, stage or predict the potential outcome of a cancer.

British Tech Network and New Products at MacWorld/iWorld 2014

SAN FRANCISCO (HighTech Reports), Moscone North, March 27, 2014 – MacWorld/ iWorld 2014. We watched a panel discussion session at the Second Stage presented by the British Tech Network (BTN) with speaker Paul Wheatley, User Experience Consultant and Host at the BTN. Paul and the panelists talked about the pros and cons of a bigger screen on the current or future iPhone, among other topics. He said that consumers are buying bigger iPhones, but the panel still preferred iPhones with smaller screens because they fit better in men’s pants pockets.

The panelists also talked about two interesting new products that they saw at the expo, BearExtender Edge and the Ring. The BearExtender Edge is long range Wi-Fi repeater/ booster that works with Macs, iPad/iPhone, and other devices (PCs with Wi-FI, other phones or tablets with Wi-Fi). The one-piece Wi-Fi repeater block plugs into an AC outlet and has an antenna that repeats/ boosts the Wi-Fi signal in the area. It does not require software or USB connector.  BearExtender also makes a high power standalone USB Wi-Fi radio adapter with an external antenna that increases the range of a Mac’s Wi-Fi signal by nearly four times that of an internal AirPort card. It adds Wi-Fi to older Macs or Windows PCs that do not have a built-in Wi-Fi adapter.

Paul and the panel were very intrigued by a new product called the Ring from Logbar, Inc., a San Carlos, California-based company.  It is a wearable technology product that fits on a finger as a finger ring.  The new Kickstarter funded device transmits hand movements or gestures to an iPhone or other Bluetooth enabled devices. The Ring works as an in-the-air pointing device that drew a largish crowd around its booth. A spokesperson from the Asian firm that is making the device suggested that the Ring is still in beta-test.

MacWorld/iWorld 2014 Returns to Moscone North

SAN FRANCISCO (HighTech Reports), Moscone North, March 27, 2014 – MacWorld/ iWorld 2014. It was refreshing to see that MacWorld/ iWorld returned to Moscone North, MacWorld’s former location of years ago. There were around 30,000 attendees at this year’s MacWorld. The exhibit floor seemed bigger than last year and highlighted more booths that we visited. We spent some time in the MacIT room where companies that had booths gave presentations. While there, we learned about products from Printer Logic, Lantronix, Absolute Software, Parallels, and Crash Plan.

Printer Logic sells an enterprise software app that attaches to Windows 2008R file server. The app replaces print server boxes in the enterprise. A license for up to 50 printers costs $5,000. The spokesperson said that most users have 25-30 printers. Each client driver for Mac/Windows PCs links to the printer app via Wi-Fi that scales very big in the enterprise. For example, the Department of Homeland Security used its service to reduce support calls for print servers that went down. The app solution was more efficient and saved the client money.

Absolute Software makes software that helps organizations manage all types of computer assets: PCs, laptops, tablets, phones, etc. It helps track the life cycle of all IT equipment assets to end-of-life. For example, the software helps Apple track iTunes content licensee IP assets. The firm’s solution helped the Columbine school track tablets, laptops, and thefts from intruders entering its campus. The company puts a special sticker on devices with a phone number to call if a child gets cyber bullied. The victimized child connects to a caring person to talk to and so forth. Absolute Software is also exploring other vertical markets.

 

Bay Area Biopharma Firms Evolve Their Mobile Apps

I recently attended the Apps World North America Conference on Feb. 5, 2014 held at, San Francisco’s Moscone West convention center. The event is driven by the huge interest in mobile apps by mobile device users, developers and device makers.   Since mobile apps are a core technology that makes mobile devices so useful, the subject of developing and commercializing mobile apps has become an important business topic to over 8000 visitors to this interesting event.

Apparently, a number of healthcare companies were doing some work in the mobile apps space that might benefit many kinds of enterprises.  Paul Lanzi, Senior. Manager of the Mobile, Web and Portal Team, Gilead Sciences, gave a talk about the Evolution of mobility in the enterprise. Paul’s team provides the infrastructure to support mobile solutions at Gilead. Paul said that he started in the tech industry in 1994 and worked at Genentech in a similar job prior to his Gilead role.

Lanzi cited recent mobile milestones by saying that change has come rapidly and best practices were learned from various experiences.  In 2012 his company’s apps development grew from 1 to 100 enterprise mobile apps. By 2013, they were creating enterprise apps that employees actually want to use. Going into 2014, he expects to see more of the evolution of enterprise mobility.  Paul said that the most common mobile devices ten years ago were the Motorola Razor and the Blackberry. Lanzi said that developers need to use the idea of Mobile First and said that “In the Net, Net things change really fast.

There are four evolutionary stages of mobility in the enterprise.

Brochureware. He gave an example of his local restaurant took their paper menu and put it on the web. That’s all they did.  He showed that pharmaceutical firms like Gilead or Genentech make brochureware of Rx package inserts. People can go online and read the drug package insert online.  It adds value above a paper version, its low cost, fast to deploy and easy to update.

Paul said that enterprise app developers need to watch out for certain things by saying that it is best to avoid making an evolutionary dead end with mobile apps. Paul used a biology evolution example to make his point that crocodiles and chickens have something in common.  At some intermediate points along the evolutionary path, dinosaur-like birds with teeth emerged that became evolutionary dead-ends and went extinct.  Similarly in the PC apps evolution, the keyboard driven command line interface evolved into the familiar windows and mouse click interface.

 Snackable Apps. Its best to mobilize a key subset of business processes, “instead of providing the whole ocean.”  For example, Lanzi said that a business app that enables “Review pending transactions, approve pending transaction” is a very simple user interface. Users at Genentech said “I approve with gApprove even when I’m sitting in front of my computer.”

He said that sometimes you get some surprises.  Once they need to needed to assign support tickets on mobile devices for facility power plant workers.  They had a new app designed, but no one used it. It turned out that a 37-yr-old designed it, but the average age of end-user was 58.  What happened is the workers at that age had worse eyesight and could not read the app. The app had 12 point type.  Lanzi said that mobilize the right part of the process,  get a deep understanding of process, and keep adjusting the app.

Full Business Processes. Paul said that Concur is a complete business process at his company designed for expense reports. Concur has done a great job of adapting with Blackberry and IOS devices.  Lanzi said that developers need to choose the right process and never stop evolving.

Mobile First Enterprise.  Paul said that developers need to consider mobile first, the philosophy, and leadership, procurement, finance, hiring, and so on. Lanzi said that enterprise app builders need to design for change. For example, when Paul was working at Genentech, he said that the sales team in Spain was given iPads to replace laptops. The sales people had to get used to doing work on that device instead of on their laptops and so forth. He said that you can contact Paul on Twitter using @planzi.

Bio Investor Forum Day 2 — Biotech IPOs

–San Francisco, the Palace Hotel, Bio Investor Forum Day 2, October 9, 2013. The meeting wrapped up with its Closing Plenary: Early Stage Venture Financing — Will Current Trends Continue in 2014? The Plenary was structured as a panel discussion that included moderator Luke Timmerman — Xconomy, Srini Akkaragu — Sofinova Ventures, Brian Atwood — Versant Ventures, Alexis Borisy — 3rd Rock Ventures, Maria Chavez — AbbVie Biotech Ventures, Andrew Schwab — 5AM Ventures.  LukeTimmerman opened the discussion by saying that the big story of  2013 is the boom in biotech IPOs.  He said that in the last few years many VCs have dropped out – about half of the VCs became vampires.

The discussion opened with comments from the panel about the string of biotech IPOs that emerged in 2013. They seemed pleased that there were IPOs and wondered if the situation was sustainable into 2014 or beyond. Others commented that a biotech IPO is at an early part of a long series of steps to make a drug and that they have seen this process over and over.

Some commented about the apparent high quality of the recent crop of companies, saying that a lot of the areas in biology have a lot of unknowns and is really risky.  Companies that are able to pick out the small pieces that are well known can go forward. The advances in biology amassed over the last twenty years has enabled many of the biotech companies to do IPOs.

As the discussion continued, the topics ranged the share of VC money invested in companies, to partnerships, syndication, and the short list of “go to” financial and VC companies.  They also spoke about crowd funding, YouTube, using big data for biomarkers.  They see change coming with Accountable Care Organizations, and reimbursement issues.

From what I could see, we can expect to see more biotech IPOs in 2014.

%d bloggers like this: